Abbvie Sculpts Position In Aesthetics Space With Allergan Acquisition
Executive Summary
Abbvie is taking on Allergan's aesthetics portfolio as part of its $63bn takeover deal. The acquisition includes Allergan's CoolSculpt body contouring system and a new FDA-approved device for muscle strengthening.
You may also be interested in...
AbbVie Pounces On Chance To Buy Revenues In $63bn Mega-Deal For Allergan
AbbVie will gain the $3.58bn Botox business, a women's health franchise and gastrointestinal products in an opportunistic acquisition intended to reduce the company's dependence on Humira.
Allergan Pays $2bn-Plus For Zeltiq, Expanding Aesthetics Business
Zeltiq's CoolSculpting body-contouring system will be the third "pillar" in Allergan's aesthetics business, along with its existing facial aesthetics and plastic and regenerative surgery lines, the company says.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.